Blockade of Endothelial-Mesenchymal Transition by a Smad3 Inhibitor Delays the Early Development of Streptozotocin-Induced Diabetic Nephropathy
Open Access
- 3 August 2010
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 59 (10), 2612-2624
- https://doi.org/10.2337/db09-1631
Abstract
OBJECTIVE A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy). We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes. In the present study, we hypothesized that blocking EndoMT reduces the early development of diabetic nephropathy. RESEARCH DESIGN AND METHODS EndoMT was induced in a mouse pancreatic microvascular endothelial cell line (MMEC) in the presence of advanced glycation end products (AGEs) and in the endothelial lineage–traceble mouse line Tie2-Cre;Loxp-EGFP by administration of AGEs, with nonglycated mouse albumin serving as a control. Phosphorylated Smad3 was detected by immunoprecipitation/Western blotting and confocal microscopy. Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 (SIS3) were performed in MMECs and in STZ-induced diabetic nephropathy in Tie2-Cre;Loxp-EGFP mice. RESULTS Confocal microscopy and real-time PCR demonstrated that AGEs induced EndoMT in MMECs and in Tie2-Cre;Loxp-EGFP mice. Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ-induced diabetic nephropathy. Confocal microscopy and real-time PCR further demonstrated that SIS3 abrogated EndoMT, reduced renal fibrosis, and retarded progression of nephropathy. CONCLUSIONS EndoMT is a novel pathway leading to early development of diabetic nephropathy. Blockade of EndoMT by SIS3 may provide a new strategy to retard the progression of diabetic nephropathy and other diabetes complications.This publication has 45 references indexed in Scilit:
- Endothelial–Mesenchymal Transition as a Novel Mechanism for Generating Myofibroblasts during Diabetic NephropathyThe American Journal of Pathology, 2009
- Endothelial-Myofibroblast Transition Contributes to the Early Development of Diabetic Renal Interstitial Fibrosis in Streptozotocin-Induced Diabetic MiceThe American Journal of Pathology, 2009
- Renal and Retinal Effects of Enalapril and Losartan in Type 1 DiabetesNew England Journal of Medicine, 2009
- Essential Role of TGF-β Signaling in Glucose-Induced Cell HypertrophyDevelopmental Cell, 2009
- PKC-β1 Mediates Glucose-Induced Akt Activation and TGF-β1 Upregulation in Mesangial CellsJournal of the American Society of Nephrology, 2009
- Fibroblasts in Kidney Fibrosis Emerge via Endothelial-to-Mesenchymal TransitionJournal of the American Society of Nephrology, 2008
- Interference with TGF-β signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuriaAmerican Journal of Physiology-Renal Physiology, 2007
- Deficiency of Endothelial Nitric-Oxide Synthase Confers Susceptibility to Diabetic Nephropathy in Nephropathy-Resistant Inbred MiceThe American Journal of Pathology, 2007
- Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuriesKidney International, 2006
- Role of TGF-β signaling in extracellular matrix production under high glucose conditionsKidney International, 2003